Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.
F. Ligorio, L. Provenzano, R. Caputo et al.· EClinicalMedicine· 0 citations
Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer (BC) represents the most common disease subtype. Although the introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) has substantially improved patient outcomes, treatment...
Letizia Matera, J. Etessami, C. Valenza et al.· Future Oncology· 0 citations
The expanding landscape of therapeutic options in patients with either germline or somatic genetic alterations of BRCA1 and BRCA2, as well as other homologous recombination genes, offers significant opportunities to improve outcomes beyond first-generation PARP inhibition.
J. Etessami, L. Tori, M. Aconito et al.· Current Opinion in Oncology· 0 citations
The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed, and a timely and cohesive synthesis of a rapidly evolving field is offered.
J. Etessami, I. Attili, P. T. Aliaga et al.· Cancer Treatment Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.